Best Medical Stocks To Invest In Right Now

As top Republicans see it, a medical malpractice crisis is threatening U.S. health care: Frivolous lawsuits are driving up malpractice insurance premiums and forcing physicians out of business. Doctors and hospitals live in fear of litigation, ordering excessive tests and treatments that make health care unaffordable for Americans.

That’s why Republican House Speaker Paul Ryan and Rep. Tom Price, tapped to be the nation’s top health official by President-elect Donald Trump, are vowing to make tort reform a key part of their replacement plan for the Affordable Care Act.

But, according to researchers and industry experts, the reality doesn’t match the GOP rhetoric. They say the nation’s medical malpractice insurance industry is running smoothly and the last crisis dates back more than a decade.

“It’s a wonderful time for doctors looking for coverage and it’s never been better for insurers,” said Michael Matray, editor of Medical Liability Monitor, a trade publication.

Best Medical Stocks To Invest In Right Now: Jagged Peak Energy Inc. (JAG)

Advisors’ Opinion:

  • [By Logan Wallace]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Jagged Peak Energy alerts:

    Jagged Peak Energy (JAG) Raised to “Hold” at Zacks Investment Research (americanbankingnews.com) Jagged Peak Energy (JAG) Upgraded to “Hold” by ValuEngine (americanbankingnews.com) Jagged Peak Energy (JAG) Set to Announce Earnings on Thursday (americanbankingnews.com) Insider Selling: Jagged Peak Energy Inc (JAG) CFO Sells 50,000 Shares of Stock (americanbankingnews.com) Jagged Peak Energy Inc (JAG) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)

    Jagged Peak Energy stock opened at $14.25 on Friday. The company has a current ratio of 0.35, a quick ratio of 0.35 and a debt-to-equity ratio of 0.22. Jagged Peak Energy has a 1-year low of $11.21 and a 1-year high of $16.55. The company has a market capitalization of $2,993.81, a P/E ratio of 54.81 and a beta of -1.13.

Best Medical Stocks To Invest In Right Now: Greenlight Capital Re Ltd.(GLRE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Note that hedge fund mogul David Einhorn has been a director ofthe predecessor company since May 2006. Mr. Einhorn co-founded, and has served as the President of, Greenlight Capital, Inc., since January 1996. Funds managed by Greenlight are some ofthe Companys principal stockholders. Since July 2004, Mr. Einhorn has served as Chairman of the Board of Greenlight Capital Re, Ltd (Nasdaq: GLRE).

Best Medical Stocks To Invest In Right Now: NiSource, Inc(NI)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Wedbush Securities Inc. raised its holdings in NiSource (NYSE:NI) by 25.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,858 shares of the utilities provider’s stock after acquiring an additional 2,800 shares during the period. Wedbush Securities Inc.’s holdings in NiSource were worth $331,000 at the end of the most recent reporting period.

  • [By Lisa Levin]

    In trading on Thursday, utilities shares fell by 2.01 percent. Meanwhile, top losers in the sector included Unitil Corporation (NYSE: UTL), down 9 percent, and NiSource Inc. (NYSE: NI), down 5 percent.

Best Medical Stocks To Invest In Right Now: Iteris, Inc.(ITI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

Best Medical Stocks To Invest In Right Now: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Trading Down 7%” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at www.tickerreport.com/banking-finance/3362849/nektar-therapeutics-nktr-trading-down-7.html.

  • [By Cory Renauer]

    Even though it’s been a rough few years for many of the industry’s larger players, some smaller upstarts have produced stunning gains lately. Shares ofNektar Therapeutics (NASDAQ:NKTR), BeiGene Ltd. (NASDAQ:BGNE), and AveXis Inc. (NASDAQ:AVXS) have risen at least 500% in less than three years.

  • [By Lisa Levin]

    Shares of Nektar Therapeutics (NASDAQ: NKTR) got a boost, shooting up 38 percent to $21.33 after the company reported that it has met its primary and secondary endpoints in Phase 3 Summit-07 study for chronic pain.

  • [By Sean Williams]

    Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.

Best Medical Stocks To Invest In Right Now: Diana Shipping inc.(DSX)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Despite a lack of conviction in the market at large, some stocks posted sharp gains on Friday, and Diana Shipping (NYSE:DSX), Akorn (NASDAQ:AKRX), and Granite Construction (NYSE:GVA) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested small cap dry bulk shippingDiana Shipping Inc (NYSE: DSX) as a short/bearish position:

  • [By Dan Caplinger]

    The stock market had a negative tone on Wednesday, although major benchmarks moved in different directions. The Dow Jones Industrials took the biggest hit, falling triple digits as one of its most influential components suffered an earnings-related drop. Relative strength in the Nasdaq Composite showed cross-currents in the overall market, but several individual stocks had substantial declines for the day, andRite Aid (NYSE:RAD), Diana Shipping (NYSE:DSX), and Finisar (NASDAQ:FNSR) were among the worst performers. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Leave a Reply

Your email address will not be published. Required fields are marked *